April, 2025Bright Peak Therapeutics Appoints John Schmid to its Board of DirectorsRead MoreJanuary, 2025Bright Peak Therapeutics To Participate in 43rd Annual J.P. Morgan Healthcare ConferenceRead MoreNovember, 2024Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Read MoreOctober, 2024Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 ImmunoconjugateRead MoreJune, 2024Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical TrialsRead MoreApril, 2024Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingRead MoreApril, 2023Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional αPD1-IL18 ImmunocytokineRead MoreNovember, 2022Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022Read MoreOctober, 2022Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel TreatmentsRead MoreOctober, 2022Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory BoardRead MoreAugust, 2022Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development Read MoreMarch, 2022Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual MeetingRead MoreFebruary, 2022Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to its Board of DirectorsRead MoreNovember, 2021Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of DirectorsRead MoreNovember, 2021Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted ImmunocytokinesRead MoreJune, 2021Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of DirectorsRead MoreMarch, 2021Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel ImmunocytokinesRead MoreApril, 2020Versant Ventures Launches Bright Peak TherapeuticsRead More
'